Register
Log in
Wishlist (0)
Shopping cart (0)

You have no items in your shopping cart.

Insight Pharma Reports

LaMerie

Sort by Display per page

Picture of Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

From $1,642.00

Picture of Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

March 2019

From $90.00

Picture of Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-ß, CXCR4, CSF-1R, CD47-SIRPa, adenosine pathway & STING 2018

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-ß, CXCR4, CSF-1R, CD47-SIRPa, adenosine pathway & STING 2018

July 2018

From $927.04

Picture of Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

July 2018

From $579.40

Picture of Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

July 2018

From $579.40

Picture of Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

July 2018

From $695.28

Picture of TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends

May 2018

From $2,538.08

Picture of Intracellular Targets made druggable by TCR-like Antibodies

Intracellular Targets made druggable by TCR-like Antibodies

February 2018

From $2,814.97

Picture of BCMA-Targeted Antibodies & T-Cells in: October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

BCMA-Targeted Antibodies & T-Cells in: October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

November 2016

From $214.34

Picture of TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016

August 2016

From $2,735.18

Picture of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016

June 2016

From $1,508.00

Picture of Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update

June 2016

From $580.00

Picture of Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

June 2016

From $580.00

Picture of RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

April 2016

From $1,069.99

Picture of Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2016 Update

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2016 Update

April 2016

From $464.00

Picture of Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

April 2016

From $232.00

Picture of Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

April 2016

From $348.00

Picture of Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

October 2014

From $253.86

Picture of Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

November 2015

From $2,487.71

Picture of Competitor Analysis: Ebola Virus Vaccines and Therapeutics

Competitor Analysis: Ebola Virus Vaccines and Therapeutics

October 2014

From $253.86

Picture of Competitor Analysis: Staphylococcus aureus Vaccines

Competitor Analysis: Staphylococcus aureus Vaccines

October 2013

From $688.40

Picture of Competitor Analysis: Herpes Virus Vaccines and Therapeutics

Competitor Analysis: Herpes Virus Vaccines and Therapeutics

December 2012

From $393.39

Picture of Competitor Analysis: Tuberculosis Vaccines and Therapeutics

Competitor Analysis: Tuberculosis Vaccines and Therapeutics

September 2012

From $516.00

Picture of Competitor Analysis: CMV Vaccines & Therapeutics

Competitor Analysis: CMV Vaccines & Therapeutics

August 2012

From $266.00

Picture of Competitor Analysis: Malaria Vaccines and Therapeutics

Competitor Analysis: Malaria Vaccines and Therapeutics

August 2012

From $390.00

Picture of Competitor Analysis: Dengue Virus Vaccines and Therapeutics

Competitor Analysis: Dengue Virus Vaccines and Therapeutics

July 2012

From $266.00

Picture of Competitor Analysis: RSV Vaccines and Therapeutic

Competitor Analysis: RSV Vaccines and Therapeutic

June 2012

From $333.00

Picture of Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics

Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics

May 2012

From $394.00

Report Topics